Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 20, 2026. See the latest report

Medy-Tox · 086900 · Biotech & Pharma

Medy-Tox: Modest Profitability, Share Price Down 40.5% Over a Year, Model Estimate Below Market Price

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Medy-Tox closed at ₩70,000 on 2026-10-19 with a market value of about ₩510.9B, down 40.5% over one year and 4.0% over one month. Trailing revenue is ₩251.1B with a 6.9% operating margin, and a discounted cash flow model estimate of ₩51,161 per share sits below the current price.

Written Oct 20, 2026 · Data as of Oct 19, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a company with steadily growing revenue and positive free cash flow, now paying a dividend and cancelling shares. Revenue rose each year shown, from ₩184.9B in 2021 to ₩247.3B in 2025. Profitability is the weak point: operating margin fell from 23.9% in 2022 to 6.9%, and ROE is 3.6%. The trailing P/E of 33.4 is high for that level of earnings, although the P/B of 1.4 is lower than at recent year-ends. Foreign ownership fell from 15.1% to 12.4% over 60 days, which shows weaker foreign demand. Whether margins recover is not something the data can answer.

Business overview

Medy-Tox is a Biotech & Pharma company listed on KOSDAQ since 2009-01-16 and founded in 2000, with 7,298,497 listed shares. Market capitalisation is ₩510.9B and enterprise value is about ₩503.0B. Revenue grew from ₩184.9B in 2021 to ₩247.3B in 2025. Other details on products or segments are not available in the data provided. A recent news item mentions the company sharing clinical findings on its toxin and filler portfolio at a Seoul conference.

Every earlier JONBUR Research report and update note on Medy-Tox, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩30,157
-55%
Base
₩51,161
-24%
Bull
₩86,212
+28%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 27, 2026Update noteModel fair value changeMedy-Tox: Model Fair Value Estimate Cut by About a Third to ₩34,974 Base Case
  2. Oct 20, 2026InitiationStart of coverage (reader request)Medy-Tox: Modest Profitability, Share Price Down 40.5% Over a Year, Model Estimate Below Market Price

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information